Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice

AIDS Research and Human Retroviruses

Volumn 19, Issue 9, 2003, Pages 817-823

  Gao, Feng ^a   Li, Yingying ^b   Decker, Julie M ^b   Peyerl, Fred W ^c   Bibollet Ruche, Frederic ^b   Rodenburg, Cynthia M ^b   Chen, Yalu ^b   Shaw, Denise R ^b   Allen, Susan ^d   Musonda, Rosemary ^e   Shaw, George M ^b,d   Zajac, Allan J ^f   Letvin, Norman ^c   Hahn, Beatrice H ^b,d,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; NEF PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELL LINE; CODON USAGE; CONTROLLED STUDY; DENSITOMETRY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOBLOTTING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS PATHOGENESIS; WILD TYPE;

AIDS VACCINES; ANIMALS; CODON; FEMALE; GENES, ENV; GENES, GAG; GENES, NEF; GENES, POL; HIV-1; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; VACCINES, DNA;

EID: 0141705294     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203769232610     Document Type: Article

References (26)

1. Pollard VW and Malim MH: The HIV-1 Rev protein. Annu Rev Microbiol 1998;52:491-532.
2. Haas J, Park EC, and Seed B: Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-324.
3. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, and Haas J: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998;72:1497-1503.
4. Schneider R, Campbell M, Nasioulas G, Felber BK, and Pavlakis GN: Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997;71:4892-4903.
5. Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, and Pavlakis GN: Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992;66:7176-7182.
6. Corbet S, Vinner L, Hougaard DM, et al.: Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses 2000;16:1997-2008.
7. zur Megede J, Chen MC, Doe B, et al.: Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000;74:2628-2635.
8. Chakrabarti BK, Kong WP, Wu BY, et al.: Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002;76:5357-5368.
9. Deml L, Bojak A, Steck S, et al.: Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001;75:10991-11001.
10. Barouch DH, Craiu A, Santra S, et al.: Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 2001;75:2462-2467.
11. Huang Y, Kong WP, and Nabel GJ: Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 2001;75:4947-4951.
12. Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-492.
13. + T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 2001;20:623-629
14. Qiu JT, Song R, Dettenhofer M, et al.: Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J Virol 1999;73:9145-9152.
15. Moore AC, Kong WP, Chakrabarti BK, and Nabel GJ: Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002;76:243-250.
16. + T-cell-depleted rhesus macaques. J Virol 2001;75:1547-1550.
17. Osmanov S, Pattou C, Walker N, Schwardlander B, and Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-190.
18. Rodenburg CM, Li Y, Trask SA, et al.: Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 2001;17:161-168.
19. Barouch DH, Santra S, Steenbeke TD, et al.: Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998;161:1875-1882.
20. Binley JM, Sanders RW, Clas B, et al.: A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an interrnolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000;74:627-643.
21. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74:8358-8367.
22. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-2864.
23. Wei X, Decker JM, Liu H, et al.: Emergence of resistant HIV-1 in patients receiving infusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
24. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
25. Wolff JA, Malone RW, Williams P, et al.: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
26. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, and Mitrophanous KA: A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000;74:4839-4852.